622 Results

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Background: Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens...

Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.

Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD...

Dupilumab in the treatment of moderate-to-severe atopic dermatitis.

Introduction: Atopic dermatitis is a common inflammatory skin disease with an increasing prevalence. Treatment of patients suffering from mild or moderate disease includes the use of emollients and topical glucocorticoids...

Avelumab and other recent advances in Merkel-cell carcinoma.

Merkel-cell carcinoma (MCC) is a rare but aggressive form of skin cancer that occurs in the elderly, is associated with UV radiation and immunosuppression. Initial treatment consists of wide excision with adjuvant radiation.

Avelumab for the treatment of metastatic Merkel cell carcinoma.

Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin.

Nivolumab plus ipilimumab in advanced melanoma.

In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab...

High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.

Systemic high-dose interleukin-2 (IL-2) achieved long-term survival in a subset of patients with advanced melanoma.

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Melanoma is the deadliest form of skin cancer and its incidence has been increasing.

Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis.

Patients with thin, low-risk melanomas have an excellent long-term prognosis and higher quality of life than those who are diagnosed at later stages.

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.

The treatment of melanoma has improved markedly over the last several years with the advent of more targeted therapies.

Load more